Brief: Apontis Pharma And Midas Pharma Announce Development Partnership
Dec 14 (Reuters) - APONTIS PHARMA AG APPHG.DE :
* APONTIS PHARMA AND MIDAS PHARMA ANNOUNCE DEVELOPMENT
PARTNERSHIP
TO LAUNCH SINGLE PILL WITH PAN-EUROPEAN INTELLECTUAL PROPERTY
RIGHTS
* CONTINUED EXPANSION OF MID-TERM
* APONTIS PHARMA FOR FIRST TIME OWNS ALL EUROPE-WIDE RIGHTS
(IP -
INTELLECTUAL PROPERTY) TO PREPARATION, MEDICATION, OR SINGLE
PILL
Source text for Eikon: ID:nEQ6GnGN2a
Further company coverage: APPHG.DE
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on Apontis Pharma AG
See all newsBrief: Bruno Wohschlegel To Leave Apontis Pharma As CEO End Of August
Brief: APONTIS PHARMA Q1 EBITDA EUR 1.3 Million
Brief: Apontis Pharma Says Zentiva AG Submits Formal Request To Carry Out A Merger
Brief: Zentiva Says Amendeds Offer To Acquire Each Outstanding Share Of Apontis Pharma In Cash By Waiving Condition Of A Minimum Acceptance
Brief: Apontis Pharma: Zentiva To Launch Voluntary Public Purchase Offer At EUR 10.00 Per Share